IMR Press / EJGO / Volume 39 / Issue 6 / DOI: 10.12892/ejgo3977.2018

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Clinical significance of atypical glandular cells in Pap tests: experience of a gynecologic oncology center in 74 patients
Show Less
1 Kanuni Sultan Suleyman Training and Research Hospital, Department of Gynecologic Oncology, Istanbul, Turkey
2 Acibadem University, Department of Obstetrics and Gynecology, Istanbul, Turkey
3 Kanuni Sultan Suleyman Training and Research Hospital, Department of Gynecology, Istanbul, Turkey
Eur. J. Gynaecol. Oncol. 2018, 39(6), 911–914; https://doi.org/10.12892/ejgo3977.2018
Published: 10 December 2018
Abstract

Purpose of the investigation: To investigate the clinical importance of atypical glandular cells (AGC) on Pap Smear Test (PST). Materials and Methods: Clinical records of 74 patients that were detected with AGC were evaluated. Results: Of the 55 patients detected with AGC-not otherwise specific (AGC-NOS), 42 (76.3%) had negative histopathologic results, eight (14.5%) patients were detected with cervical squamous intraepithelial lesions, one (1.8%) patient was detected with squamous cell cervical cancer, three (5.4%) patients with endometrial hyperplasia, and one (1.8%) patient with endometrial cancer. Of the 19 patients detected with AGC-favor neoplasia (AGC-fn), seven (36.8%) patients had negative histopathologic results, five (26.3%) patients were presented with squamous intraepithelial lesions, one (5.2%) patient was detected with adenocarcinoma in situ, two (10.5%) patients with squamous cell cervical cancer, one patient had complex atypical endometrial hyperplasia, and one (5.8%) patient with endometrial cancer. The incidence of premalignant lesions in the patients with AGC-NOS and AGC-fn was 20% and 36% and the incidence of malignant lesions in the two groups was 3.6% and 26.3%, respectively. Conclusion: Patients detected with AGC on PST should be closely followed up and evaluated by using colposcopy and endocervical and endometrial curettage.
Keywords
Atypical glandular cells
Pap smear
Management
Share
Back to top